<DOC>
	<DOCNO>NCT03089944</DOCNO>
	<brief_summary>A Phase 3b , single arm , open-label , multicenter study evaluate safety demonstrate non-inferiority sustain virologic response 12 week post dosing ( SVR12 ) rate 8 week treatment glecaprevir ( GLE ) /pibrentasvir ( PIB ) combination regimen historical SVR12 rate 12 week treatment GLE/PIB treatment-na誰ve adult chronic HCV GT 1 , 2 , 4 , 5 , 6 infection compensate cirrhosis .</brief_summary>
	<brief_title>A Study Glecaprevir ( GLE ) /Pibrentasvir ( PIB ) Treatment-Na誰ve Adults With Chronic Hepatitis C Virus ( HCV ) Genotype 1 , 2 , 4 , 5 6 Infection Compensated Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Screening laboratory result indicate Hepatitis C Virus ( HCV ) Genotype ( GT ) 1 , 2 , 4 , 5 6 infection . Positive plasma HCV antibody HCV RNA viral load great equal 1000 IU/mL Screening . Treatmentna誰ve approve investigational antiHCV medication . Participant must document cirrhotic , ChildPugh score less equal 6 . Female participant pregnant , breastfeed consider become pregnant study , approximately 30 day last dose study drug . Any current historical clinical evidence decompensated cirrhosis . Positive test result Screening hepatitis B surface antigen ( HBsAg ) anti human immunodeficiency virus antibody ( HIV Ab ) . HCV genotype perform central laboratory screen indicate genotype 3 infection coinfection one HCV genotype .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pibrentasvir</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Genotype ( GT ) 1 , 2 , 4 , 5 6</keyword>
	<keyword>Pangenotypic</keyword>
	<keyword>Hepatitis C Virus ( HCV )</keyword>
	<keyword>Glecaprevir</keyword>
	<keyword>Treatment Na誰ve</keyword>
	<keyword>Compensated Cirrhosis</keyword>
</DOC>